Friday 6 November 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
146.38
9.74
−6.24%
Follow PODD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
8 | 9 | 6 | 6 |
+8 more TTM periods Free account |
| 28.94% | 26.02% | 23.00% | 18.12% | ||
| 13.31% | 11.31% | 9.31% | 7.87% | ||
ROIC |
18.77% | 17.56% | 17.90% | 16.94% | |
Return on Tangible Assets |
19.98% | 19.11% | 16.35% | 12.03% | |
Average Days of Receivables |
78.86 | 70.37 | 68.54 | 69.67 | |
Free Cash Flow per Share |
3.75 | 3.83 | 5.54 | 4.97 | |
Free Cash Flow |
260.00 | 265.60 | 387.80 | 349.90 | |
Capital Expenditures |
(249.00) | (245.60) | (231.50) | (219.40) | |
| Other line items | |||||
Cash ROIC |
8.32% | 9.14% | 14.20% | 11.00% | |
Accounts Receivable Turnover |
5.54 | 5.91 | 6.13 | 6.14 | |
Accounts Payable Turnover |
8.53 | 8.05 | 8.11 | 16.21 | |
Inventory Turnover |
1.80 | 1.90 | 1.86 | 1.74 | |
Average Days of Payables |
66.01 | 50.96 | 65.01 | 35.64 | |
Days of Inventory on Hand |
224.68 | 200.35 | 200.73 | 215.05 | |
Tax Rate |
(0.22) | (0.24) | (0.25) | (0.27) | |
Research and Development Expense of Revenue |
11.30% | 11.33% | 11.42% | 11.12% | |
Selling, General and Administrative Expense of Revenue |
42.15% | 42.86% | 42.11% | 43.02% | |
Share Based Compensation of Revenue |
2.56% | 2.55% | 2.27% | 2.32% | |
Interest Coverage |
10.63 | 8.77 | 7.81 | 7.98 | |
Operating CF/Net income |
1.19 | 1.36 | 2.05 | 2.30 | |
Depreciation/Fixed assets |
0.11 | 0.12 | 0.11 | 0.11 | |
Capex/Depreciation |
(2.36) | (2.47) | (2.44) | (2.43) | |
Revenue per Share |
45.98 | 44.06 | 41.45 | 38.50 | |
Operating CF per Share |
7.34 | 7.38 | 8.85 | 8.09 | |
Capex per Share |
(3.59) | (3.54) | (3.31) | (3.12) | |
Capex to Sales |
0.08 | 0.08 | 0.08 | 0.08 |
Columns are period end dates · fundamentals updated 5 Nov 2026